The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab.
Simkens
L H J
LHJ
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen.
Tol
J
J
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen.
Terstappen
L W M M
LWMM
Department of Medical Cell Biophysics, Faculty of Sciences and Technology, Twente University, Enschede.
Teerenstra
S
S
Department of Epidemiology, Biostatistics, and Health Technology Assessment.
Punt
C J A
CJA
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen.
Nagtegaal
I D
ID
Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: i.nagtegaal@pathol.umcn.nl.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D019937:Diagnostic Techniques and Procedures; D018450:Disease Progression; D042783:Endothelial Cells / Q000473:pathology*; D006801:Humans; D020360:Neoadjuvant Therapy; D009360:Neoplastic Cells, Circulating / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D000068258:Bevacizumab